T Harris1, K Wong1, J Nair1, J Fediurek1, S L Deeks1,2. 1. Public Health Ontario, Toronto, ON. 2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON.
Abstract
BACKGROUND: Influenza vaccine is recommended to prevent influenza-related morbidity and mortality. Post-marketing surveillance of adverse events following influenza vaccine is essential to monitor vaccine safety, inform immunization program planning and evaluation, and build confidence in immunization. OBJECTIVE: To summarize adverse events following immunization (AEFIs) reported after receipt of influenza vaccines administered within the Universal Influenza Immunization Program in Ontario. METHODS: AEFIs following administration of influenza vaccines between September 1, 2012 and August 31, 2015 were extracted from the Integrated Public Health Information System (iPHIS) on September 1, 2015. Events were grouped by provincial surveillance definitions. Reporting rates were calculated using provincial population estimates or net doses distributed as the denominator. The standard World Health Organization definition of serious AEFIs was used. RESULTS: There were 12.1 million doses of influenza vaccine distributed in Ontario and 528 AEFIs reported following influenza vaccines administered over three seasons. The annualized reporting rate was 4.4 per 100,000 doses distributed with a significant decreasing trend over time (p<0.05). The median age was 39.6 years (range six months-96 years); children under four years of age had the highest reporting rate (3.5 per 100,000 population). Disproportionate reporting among females was observed (76.5 percent), most notably in those 18 years and older. The most frequently reported events were injection site reactions (36.2 percent of reports). Others included allergic skin reactions (21.1 percent) and rashes (17.3 percent). Serious AEFIs were rare with a reporting rate of 1.6 per million doses distributed. CONCLUSION: This assessment found a low rate of reported adverse events following influenza vaccines administered in Ontario. Most reported events were mild and resolved completely. The findings were consistent with the very good safety profile of influenza vaccines.
BACKGROUND: Influenza vaccine is recommended to prevent influenza-related morbidity and mortality. Post-marketing surveillance of adverse events following influenza vaccine is essential to monitor vaccine safety, inform immunization program planning and evaluation, and build confidence in immunization. OBJECTIVE: To summarize adverse events following immunization (AEFIs) reported after receipt of influenza vaccines administered within the Universal Influenza Immunization Program in Ontario. METHODS: AEFIs following administration of influenza vaccines between September 1, 2012 and August 31, 2015 were extracted from the Integrated Public Health Information System (iPHIS) on September 1, 2015. Events were grouped by provincial surveillance definitions. Reporting rates were calculated using provincial population estimates or net doses distributed as the denominator. The standard World Health Organization definition of serious AEFIs was used. RESULTS: There were 12.1 million doses of influenza vaccine distributed in Ontario and 528 AEFIs reported following influenza vaccines administered over three seasons. The annualized reporting rate was 4.4 per 100,000 doses distributed with a significant decreasing trend over time (p<0.05). The median age was 39.6 years (range six months-96 years); children under four years of age had the highest reporting rate (3.5 per 100,000 population). Disproportionate reporting among females was observed (76.5 percent), most notably in those 18 years and older. The most frequently reported events were injection site reactions (36.2 percent of reports). Others included allergic skin reactions (21.1 percent) and rashes (17.3 percent). Serious AEFIs were rare with a reporting rate of 1.6 per million doses distributed. CONCLUSION: This assessment found a low rate of reported adverse events following influenza vaccines administered in Ontario. Most reported events were mild and resolved completely. The findings were consistent with the very good safety profile of influenza vaccines.
Authors: Jens U Rüggeberg; Michael S Gold; José-Maria Bayas; Michael D Blum; Jan Bonhoeffer; Sheila Friedlander; Glacus de Souza Brito; Ulrich Heininger; Babatunde Imoukhuede; Ali Khamesipour; Michel Erlewyn-Lajeunesse; Susana Martin; Mika Mäkelä; Patricia Nell; Vitali Pool; Nick Simpson Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: Chatura Prematunge; Kimberly Corace; Anne McCarthy; Rama C Nair; Virginia Roth; Kathryn N Suh; Gary Garber Journal: Vaccine Date: 2014-10-28 Impact factor: 3.641
Authors: Allison L Naleway; Emily M Henkle; Sarah Ball; Sam Bozeman; Manjusha J Gaglani; Erin D Kennedy; Mark G Thompson Journal: Am J Infect Control Date: 2014-04 Impact factor: 2.918
Authors: Weigong Zhou; Vitali Pool; John K Iskander; Roseanne English-Bullard; Robert Ball; Robert P Wise; Penina Haber; Robert P Pless; Gina Mootrey; Susan S Ellenberg; M Miles Braun; Robert T Chen Journal: MMWR Surveill Summ Date: 2003-01-24
Authors: Kari Bohlke; Robert L Davis; S M Marcy; M M Braun; Frank DeStefano; Steven B Black; John P Mullooly; Robert S Thompson Journal: Pediatrics Date: 2003-10 Impact factor: 7.124
Authors: Chi Yon Seo; Mohammed Rashid; Tara Harris; Jody Stapleton; Shelley L Deeks Journal: Paediatr Child Health Date: 2019-04-08 Impact factor: 2.253